Why the study?
Does bivalirudin started during transport improve 30-day clinical outcomes in patients undergoing primary PCI?
Does bivalirudin started during transport improve 30-day clinical outcomes in patients undergoing primary PCI?
Pre-hospital administration of bivalirudin for primary PCI improves 30-day outcomes and reduces bleeding, but increases the risk of acute stent thrombosis.
Answers are grounded in this paper and cite their sources.
May support prehospital bivalirudin in primary PCI for lower bleeding; leaves open mitigation of acute stent thrombosis.
Bivalirudin, started during transport for primary PCI, improved 30-day clinical outcomes with a reduction in major bleeding but with an increase in acute stent thrombosis. (Funded by the Medicines Company; EUROMAX ClinicalTrials.gov number, NCT01087723.).
No takes yet. Share an insight, caveat, or question.
Steg et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: